Author

F. Fratev

Primary ORCID profile (0000-0002-9651-9442 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

F. FrateviD3 papers · The University of Texas at El Paso

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein structure· 1 Assay:structural biology· 1

Frequent Co-Authors

E. Padilla· 1 shared M. Miranda-Arango· 1 shared S. Sirimulla· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

3 top collaborators · 3 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiophysics

E. Padilla

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The High Transmission of SARS-CoV-2 Omicron (B.1.1.529) Variant is Not Only Due to Its hACE2 binding: A Free Energy of Perturbation Study

This paper uses free energy of perturbation calculations to analyze how mutations in the SARS-CoV-2 Omicron spike protein affect RBD-hACE2 binding, showing some mutations increase binding while others decrease it.

bioRxiv · Dec 4, 2021 · PreprintBiochemistry

Discovery of New Classes of Glycine transporter 2 (GlyT2) Inhibitors and Study of GlyT2 Selectivity by Combination of Novel Structural Based Virtual Screening Approach and Free Energy Perturbation (FEP+) Calculations

F. Fratev, M. Miranda-Arango, E. Padilla, S. Sirimulla

The paper discovers new GlyT2 inhibitors with high selectivity over GlyT1 using virtual screening and FEP+ calculations, and suggests potential for treating chronic pain and pancreatic cancer.

bioRxiv · Jan 4, 2019 · PreprintBiophysics